- Conditions
- Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury
- Interventions
- NVG-291, Placebo Injection
- Drug
- Lead sponsor
- NervGen Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 833
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nasal Polyps, Chronic Rhinosinusitis
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
- Conditions
- Healthy Participants
- Interventions
- Lu AG22515, Placebo, Immune System Activator
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 19 Years to 60 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Long Beach, California • Secaucus, New Jersey
- Conditions
- Healthy Participants
- Interventions
- CDX-622, Normal Saline
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Sjögren's Syndrome, Sjogren's Syndrome
- Interventions
- SAR441344, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- DeBary, Florida • Duncansville, Pennsylvania • Memphis, Tennessee + 1 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1, Golimumab Dose 2, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more
- Conditions
- Acute Gout
- Interventions
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 96
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more
- Conditions
- Alzheimer's Disease
- Interventions
- ABBV-1758, Placebo for ABBV-1758
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Irvine, California • Boulder, Colorado • Bradenton, Florida + 8 more
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 47
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more
- Conditions
- Arthritis, Juvenile Idiopathic
- Interventions
- Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
- Biological · Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
- Conditions
- Prurigo Nodularis
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Saint Joseph, Missouri
- Conditions
- Multiple Sclerosis
- Interventions
- ELND002, Placebo
- Drug
- Lead sponsor
- Elan Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 17
- States / cities
- Berkeley, California • Fresno, California • Newport Beach, California + 14 more
- Conditions
- Systemic Sclerosis
- Interventions
- Placebo, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- El Cajon, California • Fullerton, California • Los Angeles, California + 12 more
- Conditions
- Mixed Dyslipidemia
- Interventions
- ARO-APOC3, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Northridge, California • Boca Raton, Florida + 11 more
- Conditions
- Healthy
- Interventions
- Placebo SC Injection, ATR-107 (PF-05230900) SC Injection, ATR-107 (PF-05230900) IV Infusion, Placebo IV Infusion
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Overland Park, Kansas
- Conditions
- Healthy Volunteer
- Interventions
- ABBV-142, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Grayslake, Illinois
- Conditions
- Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
- Interventions
- Relamorelin, Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 70
- States / cities
- Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 58 more
- Conditions
- Dermatitis
- Interventions
- Placebo, Risankizumab
- Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 35 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2189265, Sitagliptin, Placebo solution, Placebo tablet, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 35
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 32 more
- Conditions
- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
- Interventions
- Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 41
- States / cities
- Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more
- Conditions
- Psoriasis, Plaque Psoriasis
- Interventions
- Certolizumab Pegol, Placebo
- Biological · Other
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
- Conditions
- Hypercholesterolemia
- Interventions
- PF-05335810 Dose A, PF-05335810 Dose B, Placebo, PF-04950615 Dose A, PF-05335810 Dose C, PF-04950615, PF-05335810 Dose D, PF-05335810 Dose E
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Miami, Florida • South Miami, Florida + 4 more
- Conditions
- Hypertension
- Interventions
- Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 663 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 74
- States / cities
- Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more
- Conditions
- Resistant Hypertension
- Interventions
- XXB750 drug, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Sacramento, California + 15 more